Sales reach DKK 122.0 billion as oral semaglutide is approved

Novo Nordisk reported 2019 sales of DKK 122.0 billion, a 9% increase in Danish kroner, with operating profit reaching DKK 52.5 billion, according to the company's annual report filed with the U.S. Securities and Exchange Commission ^[1]. The filing also states that Novo Nordisk held a 47.5% value share of the global GLP-1 market that year ^[1].

The sales growth came during a year when oral semaglutide, now sold in the US as Rybelsus, moved through the regulatory approval process ^[1]. Semaglutide is the same active ingredient found in the injectable drugs Ozempic and Wegovy, but the oral version offered a pill-based alternative for patients who wanted to avoid injections ^[1]. The 20-F filing, submitted for the fiscal year ended December 31, 2019, details the company's full financial results and includes information on its diabetes and obesity care business lines ^[1].

The filing does not break out exact 2019 revenue figures specific to semaglutide products by country or by injectable versus oral formulation in the excerpt provided, so it is not yet known from this document how much of the DKK 122.0 billion total came specifically from GLP-1 sales in the United States ^[1]. What is documented is the overall company-wide sales and profit figures and the company's stated share of the global GLP-1 market ^[1].

Why it matters for patients

For patients considering or already using GLP-1 medications, the approval of an oral form of semaglutide during this period mattered because it gave people who dislike or cannot use injections another way to access the same active drug ingredient found in Ozempic ^[1]. This expanded the range of options available through prescribers in the United States.

The scale of Novo Nordisk's business, as reflected in the DKK 122.0 billion in sales and 47.5% share of the global GLP-1 market, shows how central these medications had already become to the company by 2019, years before Wegovy's obesity indication and the broader surge in public attention to GLP-1 drugs ^[1]. A company with a large share of a growing market can affect supply, pricing negotiations, and how quickly new formulations become available to patients, though the filing itself does not detail specific effects on US drug pricing or availability ^[1].

The filing is a corporate financial disclosure, not a clinical study, so it does not provide safety or efficacy data comparing the oral and injectable forms of semaglutide. Patients weighing formulation choices would need to look at separate clinical and regulatory sources for that information, which is not part of this filing ^[1].

What happens next

The 20-F covers the fiscal year ended December 31, 2019, and was filed with the SEC in early 2020 ^[1]. The document does not itself project future sales or outline specific upcoming milestones beyond the reporting period covered, so later developments in the GLP-1 market, including subsequent approvals and sales growth, are not addressed in this filing ^[1].